Clinical trial · Interventional
Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer
Integration of SPECT/CT Lymphoscintigraphy Into Breast Cancer Radiation for LymphaticSparing
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as single-photon emission computed tomography and computed tomography lymphoscintigraphy, may help lower the dose of radiation therapy after surgery, and help prevent lymphedema. PURPOSE: This clinical trial is studying single-photon emission computed tomography and computed tomography lymphoscintigraphy followed by intensity-modulated radiation therapy to see how well they work in treating patients who have undergone surgery for stage I or stage II breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Lymphedema | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| computed tomography | Procedure | — | UNRESOLVED |
| intensity-modulated radiation therapy | Radiation | — | UNRESOLVED |
| lymphoscintigraphy | Procedure | — | UNRESOLVED |
| screening questionnaire administration | Other | — | UNRESOLVED |
| single photon emission computed tomography | Procedure | — | UNRESOLVED |
| technetium Tc 99m sulfur colloid | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Philips Precedence SPECT/CT® and GE PET/CT Fusion software integration
- measure
- Dosimetry differences between 3-D conformal radiotherapy with vs without the Philips Precedence SPECT/CT®
- measure
- Lymph node dosimetry differences between single photon emission computed tomography (SPECT) and computed tomography (CT) with 3-D conformal radiotherapy vs intensity-modulated radiotherapy
- measure
- Association between radiation exposure and limb volume, circumferential wrist measurements, circumferential forearm measurements, and extra-cellular fluid measurements
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Biopsy-proven primary invasive breast cancer, meeting one of the following criteria: * Stage I or II disease with negative sentinel or axillary node dissections * Stage II disease with micrometastases (defined as \< 2.0 mm focus) in 1-2 lymph nodes and/or a single positive axillary node ≤ 1 cm with no extracapsular extension * Completed all surgical intervention (e.g., lumpectomy, mastectomy) * Planning adjuvant whole breast irradiation including the low axilla * No bilateral or recurrent breast cancer PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Not pregnancy or nursing * Negative pregnancy test * Able to complete questionnaire(s) alone or with assistance * No active infection * No history of invasive cancer within the past 5 years, except basal cell or squamous cell skin cancers PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior surgery or radiation to the ipsilateral breast or axilla * No concurrent neoadjuvant chemotherapy or radiotherapy
References
Publications (0)
Data not yet available